Skip to main content
. Author manuscript; available in PMC: 2022 Jul 6.
Published in final edited form as: Drug Dev Res. 2003 Apr;58(4):330–339. doi: 10.1002/ddr.10168

Fig. 7.

Fig. 7.

Functional effects of constitutively active mutant human A3 ARs [Chen et al 2001] (A) and enhancement of binding affinity of a human neoceptor derived from the A3 AR, upon of a complementary functional group in the neoligand [Jacobson et al., 2001] (B).